CPSE:ORPHA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases.


Snowflake Analysis

Adequate balance sheet with moderate growth potential.

Share Price & News

How has Orphazyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ORPHA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

6.4%

ORPHA

-1.5%

DK Biotechs

0.002%

DK Market


1 Year Return

119.3%

ORPHA

35.8%

DK Biotechs

23.4%

DK Market

Return vs Industry: ORPHA exceeded the Danish Biotechs industry which returned 36.1% over the past year.

Return vs Market: ORPHA exceeded the Danish Market which returned 22.3% over the past year.


Shareholder returns

ORPHAIndustryMarket
7 Day6.4%-1.5%0.002%
30 Day16.6%6.2%7.8%
90 Day-5.5%10.3%3.9%
1 Year119.3%119.3%36.8%35.8%25.8%23.4%
3 Yearn/a28.8%26.1%41.5%29.7%
5 Yearn/a65.6%60.4%53.5%34.2%

Price Volatility Vs. Market

How volatile is Orphazyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Orphazyme undervalued compared to its fair value and its price relative to the market?

40.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ORPHA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ORPHA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ORPHA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ORPHA is unprofitable, so we can't compare its PE Ratio to the Danish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ORPHA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ORPHA is overvalued based on its PB Ratio (40.3x) compared to the XE Biotechs industry average (4.4x).


Next Steps

Future Growth

How is Orphazyme forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

37.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORPHA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: ORPHA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ORPHA's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if ORPHA's revenue is forecast to grow faster than the Danish market.

High Growth Revenue: Insufficient data to determine if ORPHA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ORPHA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Orphazyme performed over the past 5 years?

-43.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ORPHA is currently unprofitable.

Growing Profit Margin: ORPHA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ORPHA is unprofitable, and losses have increased over the past 5 years at a rate of -43.7% per year.

Accelerating Growth: Unable to compare ORPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORPHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).


Return on Equity

High ROE: ORPHA has a negative Return on Equity (-637.16%), as it is currently unprofitable.


Next Steps

Financial Health

How is Orphazyme's financial position?


Financial Position Analysis

Short Term Liabilities: ORPHA's short term assets (DKK148.2M) exceed its short term liabilities (DKK66.0M).

Long Term Liabilities: ORPHA's short term assets (DKK148.2M) exceed its long term liabilities (DKK61.8M).


Debt to Equity History and Analysis

Debt Level: ORPHA's debt to equity ratio (121.6%) is considered high.

Reducing Debt: Insufficient data to determine if ORPHA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ORPHA has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: ORPHA is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Orphazyme's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORPHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORPHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORPHA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORPHA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORPHA's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Kim Stratton (57yo)

0.67

Tenure

Ms. Kim Stratton has been Chief Executive Officer of Orphazyme A/S since October 1, 2019. Ms. Stratton has been a Director at Vifor Pharma AG since May 08, 2019. Ms. Stratton was the Head of International  ...


Leadership Team

NamePositionTenureCompensationOwnership
Kim Stratton
Chief Executive Officer0.67yrno datano data
Thomas Jensen
Co-Founder & Chief Scientific Officer11.42yrsno datano data
Anders Vadsholt
Chief Financial Officer4.08yrsno data0.49% DKK14.2m
Thomas Blaettler
Chief Medical Officer3.58yrsno datano data

3.8yrs

Average Tenure

51yo

Average Age

Experienced Management: ORPHA's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Martijn Kleijwegt
Independent Director3.42yrsno datano data
Rémi Droller
Independent Director5.42yrsno datano data
Georges Gemayel
Independent Chairman5.83yrsno data0.36% DKK10.4m
Bo Hansen
Independent Deputy Chairman3.42yrsno data0.37% DKK10.8m
Sten Verland
Independent Director10.42yrsno datano data
Anders Hedegaard
Independent Director2.58yrsno data0.051% DKK1.5m
Catherine Moukheibir
Independent Director3.42yrsno data0.030% DKK854.0k
Martin Bonde
Independent Director10.42yrsno data0.17% DKK4.9m

4.4yrs

Average Tenure

59.5yo

Average Age

Experienced Board: ORPHA's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.3%.


Top Shareholders

Company Information

Orphazyme A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orphazyme A/S
  • Ticker: ORPHA
  • Exchange: CPSE
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ø2.894b
  • Shares outstanding: 27.04m
  • Website: https://www.orphazyme.com

Number of Employees


Location

  • Orphazyme A/S
  • Ole MaalOees Vej 3
  • Copenhagen
  • Capital Region of Denmark
  • 2200
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORPHACPSE (OMX Nordic Exchange Copenhagen)YesCommon SharesDKDKKNov 2017
1TBDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2017
0CUMLSE (London Stock Exchange)YesCommon SharesGBDKKNov 2017
OZYM.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDNov 2017

Biography

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/03 00:56
End of Day Share Price2020/06/02 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.